Evidence
Am J Physiol Endocrinol Metab. 2024 Mar 20. doi: 10.1152/ajpendo.00260.2023. Online ahead of print.
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with increasing prevalence worldwide. NAFLD could develop from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) causing fibrosis, cirrhosis and even hepatocellular carcinoma. However, the mechanism of NAFLD development was still not be fully defined. Recently, there are emerging evidence showing the dysregulated iron metabolism with elevated serum ferritin and ferroptosis are involved in the NAFLD. The iron metabolism and ferroptosis would shed some light on the mechanisms of NAFLD development. Here, we summarized the studies concerning iron metabolism and ferroptosis process involving in NAFLD development to highlight the potential medicament and therapies in treating NAFLD.
PMID:38506752 | DOI:10.1152/ajpendo.00260.2023
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
🌐 90 Days
VR Related Evidence Matrix
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Bacteroides and NAFLD: pathophysiology and therapy
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Emerging roles of RNA-binding proteins in fatty liver disease
- Tanshinone _A inhibits ferroptosis via Nrf2 signaling pathway to protect liver in rats of non-alcoholic fatty liver disease
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
- Effects of Ganjianglingzhu Decoction on Lean Non-Alcoholic Fatty Liver Disease in Mice Based on Untargeted Metabolomics
- Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications
- Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Associations of arsenic exposure and arsenic metabolism with the risk of non-alcoholic fatty liver disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Triglyceride Glucose Index is Associated with Ultrasonographic Fatty Liver Indicator in Children and Adolescents with Non-alcoholic Fatty Liver Disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Occult liver disease: a multinational perspective
- Relation between non-alcoholic fatty liver disease and carotid artery intimal media thickness as a surrogate for atherosclerosis: a systematic review and meta-analysis
- Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease
- Compare the Combined Diagnostic Accuracy of Transient Elastography and Visual Liver Score in Assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Compare it with Liver Biopsy in Morbidly Obese Patients Undergoing Bariatric Surgery: An…
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Role of prostaglandin E2 and its receptors in chronic liver disease
- In Vitro to In Vivo Scalars for Drug Clearance in Non-Alcoholic Fatty Liver and Steatohepatitis
- The gut-liver axis in fatty liver disease: role played by natural products
- Bioengineering scalable and drug-responsive in vitro human multicellular non-alcoholic fatty liver disease microtissues encapsulated in the liver extracellular matrix-derived hydrogel
- PINK1/Park2-Mediated Mitophagy Relieve Non-Alcoholic Fatty Liver Disease
- Evaluating the efficacy of GIPR agonists on non-alcoholic fatty liver disease: A Mediation Mendelian Randomization Study
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Associations of Ultrasound Findings with Serum Iron and Ferritin Levels in Children with Obesity
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Links between gut microbiome, metabolome, clinical variables and non-alcoholic fatty liver disease severity in bariatric patients
- Association between sleep duration and a new onset of nonalcoholic fatty liver disease
- Integrated spatial metabolomics and transcriptomics decipher the hepatoprotection mechanisms of wedelolactone and demethylwedelolactone on non-alcoholic fatty liver disease
Evidence Blueprint
Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
🌐 365 Days
VR Related Evidence Matrix
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Inhibition of free heme-catalyzed Fenton-like reaction prevents non-alcoholic fatty liver disease by hepatocyte-targeted hydrogen delivery
- Dissecting the potential role of ferroptosis in liver diseases: an updated review
- Melatonin Ameliorates Hepatic Ferroptosis in NAFLD by Inhibiting ER Stress via the MT2/cAMP/PKA/IRE1 Signaling Pathway
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Metformin alleviates hepatic iron overload and ferroptosis through AMPK-ferroportin pathway in HFD-induced NAFLD
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Depletion of Igfbp7 alleviates zebrafish NAFLD progression through inhibiting hepatic ferroptosis
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Corrected and republished from: Metabolic associated liver disease
- Bacteroides and NAFLD: pathophysiology and therapy
- Iron status and non-alcoholic fatty liver disease: A Mendelian randomization study
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
- Why do some glucose-lowering agents improve non-alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: new insights from pathogenic mechanisms to clinically targeted therapy
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Bioinformatics analysis of ferroptosis-related genes and immune cell infiltration in non-alcoholic fatty liver disease
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis
- Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
- MiR-18 regulates lipid metabolism of non-alcoholic fatty liver disease via IGF1
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease
- TIME-RESTRICTED FEEDING COMBINED WITH RESISTANCE EXERCISE TRAINING PREVENTS OBESITY AND IMPROVES LIPID METABOLISM IN THE LIVER OF MICE FED A HIGH-FAT DIET
- Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
- Liver fat as risk factor of hepatic and cardiometabolic diseases
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model
- Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet
- Dissecting the role of cadmium, lead, arsenic, and mercury in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
- High-cholesterol diet in combination with hydroxypropyl-beta-cyclodextrin induces NASH-like disorders in the liver of rats
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
- Emerging roles of RNA-binding proteins in fatty liver disease
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Tanshinone _A inhibits ferroptosis via Nrf2 signaling pathway to protect liver in rats of non-alcoholic fatty liver disease
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Anthocyanin: A Potential Phytochemical Candidate for the Amelioration of Non-Alcoholic Fatty Liver Disease
- Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
- Glucosinolates Extracts from Brassica juncea Ameliorate HFD-Induced Non-Alcoholic Steatohepatitis
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD